What Is the Indication Under Review? The indication under review is the detection, using artificial intelligence (AI) software, of large vessel occlusion (LVO) (i.e., ischemic stroke) and intracranial hemorrhage (ICH) (i.e., hemorrhagic stroke) for people of any age with a suspected acute stroke. What Is RapidAI? RapidAI is an AI-enabled software platform that facilitates the viewing, processing, and analysis of CT imaging to aid clinicians in assessing patients, including those with suspected stroke. It builds on the original RAPID software, initially developed to automate and expedite the postprocessing of CT perfusion imaging. Currently, the platform also incorporates modules that perform AI-driven detection of LVO and ICH, which were the functionalities evaluated in this review. RapidAI is intended to complement, rather than replace, clinician interpretation of CT imaging and is to be used as a supportive tool rather than a standalone diagnostic intervention. What Is the Health Technology Expert Review Panel Recommendation for RapidAI? In locations where RapidAI has already been implemented for use in detecting suspected LVO and ICH, the Health Technology Expert Review Panel (HTERP) recommends RapidAI is used only as indicated, alongside clinician interpretation of CT imaging, to reduce the risk of incorrect results; and the generation of evidence to evaluate its value in health care systems, including its use in less-resourced centres with limited access to stroke care specialists. In locations considering the implementation of RapidAI for use in detecting suspected LVO and ICH, given the uncertainty and gaps in the evidence regarding clinical, economic, and equity value of RapidAI, HTERP cannot provide recommendations for or against its implementation.
Read full abstract